Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Brukinsa (zanubrutinib)
i
Other names:
BGB-3111, BGB 3111, BGB3111
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(55)
News
Trials
Company:
BeiGene, Medison
Drug class:
BTK inhibitor
Related drugs:
‹
ibrutinib (186)
acalabrutinib (41)
orelabrutinib (23)
pirtobrutinib (14)
TG-1701 (7)
CG-806 (6)
M7583 (4)
DZD9008 (3)
JNJ-4681 (2)
abivertinib (1)
SRX3262 (1)
LOU064 (1)
SNS-062 (1)
AS-1763 (0)
DTRM-555 (0)
DTRMWXHS-12 (0)
DZD8586 (0)
GB5121 (0)
HMPL-760 (0)
HZ-A-018 (0)
KIN-8194 (0)
LP-168 (0)
NRX0492 (0)
TT-01488 (0)
tirabrutinib (0)
GDC-0853 (0)
MK-1026 (0)
HM71224 (0)
CC-292 (0)
ibrutinib (186)
acalabrutinib (41)
orelabrutinib (23)
pirtobrutinib (14)
TG-1701 (7)
CG-806 (6)
M7583 (4)
DZD9008 (3)
JNJ-4681 (2)
abivertinib (1)
SRX3262 (1)
LOU064 (1)
SNS-062 (1)
AS-1763 (0)
DTRM-555 (0)
DTRMWXHS-12 (0)
DZD8586 (0)
GB5121 (0)
HMPL-760 (0)
HZ-A-018 (0)
KIN-8194 (0)
LP-168 (0)
NRX0492 (0)
TT-01488 (0)
tirabrutinib (0)
GDC-0853 (0)
MK-1026 (0)
HM71224 (0)
CC-292 (0)
›
Associations
(55)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Marginal Zone Lymphoma
No biomarker
Marginal Zone Lymphoma
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Waldenstrom Macroglobulinemia
No biomarker
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Chronic Lymphocytic Leukemia
No biomarker
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Small Lymphocytic Lymphoma
No biomarker
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
zanubrutinib
Sensitive: A1 - Approval
zanubrutinib
Sensitive
:
A1
No biomarker
Follicular Lymphoma
No biomarker
Follicular Lymphoma
obinutuzumab + zanubrutinib
Sensitive: A1 - Approval
obinutuzumab + zanubrutinib
Sensitive
:
A1
obinutuzumab + zanubrutinib
Sensitive: A1 - Approval
obinutuzumab + zanubrutinib
Sensitive
:
A1
TP53 mutation
Small Lymphocytic Lymphoma
TP53 mutation
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
Chr del(17p)
Small Lymphocytic Lymphoma
Chr del(17p)
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
TP53 mutation
Chronic Lymphocytic Leukemia
TP53 mutation
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
Chr del(17p)
Chronic Lymphocytic Leukemia
Chr del(17p)
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
TP53 mutation + Chr del(17p)
Chronic Lymphocytic Leukemia
TP53 mutation + Chr del(17p)
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
TP53 wild-type
Small Lymphocytic Lymphoma
TP53 wild-type
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
TP53 wild-type
Chronic Lymphocytic Leukemia
TP53 wild-type
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
No biomarker
Mantle Cell Lymphoma
No biomarker
Mantle Cell Lymphoma
rituximab + zanubrutinib
Sensitive: A2 - Guideline
rituximab + zanubrutinib
Sensitive
:
A2
rituximab + zanubrutinib
Sensitive: A2 - Guideline
rituximab + zanubrutinib
Sensitive
:
A2
No biomarker
Hairy Cell Leukemia
No biomarker
Hairy Cell Leukemia
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
zanubrutinib
Sensitive: A2 - Guideline
zanubrutinib
Sensitive
:
A2
Chr del(11q)
Chronic Lymphocytic Leukemia
Chr del(11q)
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
Chr del(11q)
Small Lymphocytic Lymphoma
Chr del(11q)
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
MYD88 L265P
Waldenstrom Macroglobulinemia
MYD88 L265P
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
MYD88 wild-type
Waldenstrom Macroglobulinemia
MYD88 wild-type
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
MYD88 mutation
Waldenstrom Macroglobulinemia
MYD88 mutation
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
CXCR4 mutation
Waldenstrom Macroglobulinemia
CXCR4 mutation
Waldenstrom Macroglobulinemia
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
IGH mutation
Small Lymphocytic Lymphoma
IGH mutation
Small Lymphocytic Lymphoma
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
IGH mutation
Chronic Lymphocytic Leukemia
IGH mutation
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
NOTCH1 mutation
Chronic Lymphocytic Leukemia
NOTCH1 mutation
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
BRAF mutation
Chronic Lymphocytic Leukemia
BRAF mutation
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
ATM mutation
Chronic Lymphocytic Leukemia
ATM mutation
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
SF3B1 mutation
Chronic Lymphocytic Leukemia
SF3B1 mutation
Chronic Lymphocytic Leukemia
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
zanubrutinib
Sensitive: B - Late Trials
zanubrutinib
Sensitive
:
B
CD79B mutation
Diffuse Large B Cell Lymphoma
CD79B mutation
Diffuse Large B Cell Lymphoma
zanubrutinib
Sensitive: C2 – Inclusion Criteria
zanubrutinib
Sensitive
:
C2
zanubrutinib
Sensitive: C2 – Inclusion Criteria
zanubrutinib
Sensitive
:
C2
TP53 mutation
Mantle Cell Lymphoma
TP53 mutation
Mantle Cell Lymphoma
venetoclax + obinutuzumab + zanubrutinib
Sensitive: C2 – Inclusion Criteria
venetoclax + obinutuzumab + zanubrutinib
Sensitive
:
C2
venetoclax + obinutuzumab + zanubrutinib
Sensitive: C2 – Inclusion Criteria
venetoclax + obinutuzumab + zanubrutinib
Sensitive
:
C2
CD79B mutation
Diffuse Large B Cell Lymphoma
CD79B mutation
Diffuse Large B Cell Lymphoma
zanubrutinib
Sensitive: C2 – Inclusion Criteria
zanubrutinib
Sensitive
:
C2
zanubrutinib
Sensitive: C2 – Inclusion Criteria
zanubrutinib
Sensitive
:
C2
CD79B mutation
Diffuse Large B Cell Lymphoma
CD79B mutation
Diffuse Large B Cell Lymphoma
rituximab + zanubrutinib
Sensitive: C2 – Inclusion Criteria
rituximab + zanubrutinib
Sensitive
:
C2
rituximab + zanubrutinib
Sensitive: C2 – Inclusion Criteria
rituximab + zanubrutinib
Sensitive
:
C2
TP53 mutation
Diffuse Large B Cell Lymphoma
TP53 mutation
Diffuse Large B Cell Lymphoma
rituximab + zanubrutinib
Sensitive: C2 – Inclusion Criteria
rituximab + zanubrutinib
Sensitive
:
C2
rituximab + zanubrutinib
Sensitive: C2 – Inclusion Criteria
rituximab + zanubrutinib
Sensitive
:
C2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login